Ondine's Steriwave Phase 3 Trial Reaches 93% Enrollment Milestone in Landmark Surgical Site Infection Prevention Study

Ondine Biomedical (搜索)搜索该词条 has achieved a significant milestone in its Phase 3 LANTERN trial, reaching 93% enrollment for its investigational nasal photodisinfection technology Steriwave查看药品详情. The landmark study is evaluating the non-antibiotic treatment as a potential alternative to current standard care for preventing surgical site infections (搜索)搜索该疾病 (SSIs), bringing the Canadian life sciences company closer to its planned FDA submission.

Addressing a Critical Healthcare Challenge

The LANTERN study (Light-Activated Antimicrobial Nasal Therapy to Prevent Surgical Site Infections (搜索)搜索该疾病) represents one of the most significant investigations into universal nasal decolonization to date. Currently, there is no FDA-approved drug or device specifically indicated for the prevention of SSIs in the United States, highlighting the critical unmet medical need this technology aims to address.

Healthcare-associated infections (搜索)搜索该疾病 cost the U.S. healthcare system approximately $35 billion annually, with antibiotic resistance reaching up to 70% for some treatments in certain regions. The medical community faces an urgent need for non-antibiotic alternatives that don't contribute to the growing global crisis of antimicrobial resistance.

Revolutionary Treatment Approach

Steriwave查看药品详情 uses a patented photodisinfection process where a light-activated photosensitizer is applied to the nasal passages and activated by a specific wavelength of red light, triggering an oxidative burst that eliminates bacteria, viruses, and fungi in minutes. This represents a significant departure from current standard care protocols.

The current standard of care is the antibiotic mupirocin查看药品详情, which requires five days of self-administration at home, often resulting in compliance rates as low as 30-40%. In contrast, Steriwave查看药品详情 is administered by a nurse-assistant in just five minutes, ensuring 100% adherence immediately prior to surgery without contributing to antimicrobial resistance.

Study Scale and Progress

The LANTERN trial involves over 5,000 surgical patients across 14 HCA Healthcare查看公司主页 hospitals in the United States and four major Canadian centers. The study has demonstrated exceptional data integrity, with 92% of clinical report forms complete and participant retention exceeding 98%.

Carolyn Cross, CEO of Ondine Biomedical (搜索)搜索该词条, emphasized the study's significance: "The LANTERN study represents a landmark investigation into the potential for universal nasal decolonization to meaningfully reduce surgical site infections (搜索)搜索该疾病. As we approach full enrollment, we look forward to sharing our top-line results and moving forward with our FDA submission to address this multi-billion-dollar burden on the U.S. healthcare system."

Regulatory Status and Global Deployment

The Food and Drug Administration has granted Steriwave查看药品详情 Qualified Infectious Disease Product designation and Fast Track status, recognizing its potential to address significant unmet medical needs. Top-line results from the LANTERN study are expected in Spring 2026, following the completion of endpoint adjudication and database lock.

Outside the United States, Ondine's photodisinfection technology is already cleared for use and currently utilized in hospitals across the UK, EU, and Canada. In these regions, it is used preoperatively for patients undergoing surgical procedures and for infection control in Intensive Care Units (ICUs).

Company Background

Ondine Biomedical (搜索)搜索该词条 Inc. is a Canadian life sciences company focused on light-activated antimicrobial therapies, with a pipeline of investigational products based on its photodisinfection technology. The company's nasal photodisinfection system is CE-marked in Europe and approved for nasal decolonization in Canada, Australia, Mexico, and several other countries under the name Steriwave查看药品详情.